welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: March 1, 2003
estimated completion: Not Available
last updated: September 29, 2017
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Phenotype and Management of Patients with Familial Adenomatous Polyposis in Hong Kong: Perspective of the Hereditary...OBJECTIVES : To report on the phenotypic...
Chemoprevention of Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) has...
Ileal Pouch Anal Anastomosis: Analysis of Outcome and Quality of Life in 3707 PatientsBACKGROUND : Ileal pouch anal anastomosi...
Bonnies Diary Feb 08https://jtvcancersupport.com/embed/30453...
Desmoid Tumors: Clinical Features and Treatment Options for Advanced DiseaseDesmoid tumors describe a rare monoclona...
High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid TumorsBACKGROUND : Desmoid tumors are mesenchy...
Restorative Proctectomy with Ileal Pouch-Anal Anastomosis in Obese PatientsPURPOSE : The aim of this study was to a...